Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jesse Shefferman Insider Profile
11 Followers
Jesse Shefferman, CEO & President, Director at Protara Therapeutics, holds 944.06K shares in Protara Therapeutics (Ticker: TARA).
Jesse Shefferman has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jesse Shefferman's holdings
Insider Roles
CEO & President, Director
Roles that Jesse Shefferman holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Aug 15, 2022 - Aug 15, 2023
Return:-31.70%
The most profitable trade made by Jesse Shefferman
Jesse Shefferman's Trading History
List of latest transactions for each holding click on a transaction to see Jesse Shefferman's performance on stock
You May Also Like
Jesse Shefferman insider profile FAQ
What is the percentage of profitable transactions made by Jesse Shefferman?
The percentage of profitable transactions made by Jesse Shefferman is ―.
What is the average return per transaction made by Jesse Shefferman?
The average return per transaction made by Jesse Shefferman is ―.
What stocks does Jesse Shefferman hold?
Jesse Shefferman holds: TARA stocks.
What was Jesse Shefferman’s latest transaction?
Jesse Shefferman latest transaction was an Uninformative Buy of ―.
What was Jesse Shefferman's most profitable transaction?
Jesse Shefferman’s most profitable transaction was an Informative Buy of TARA stock on August 15, 2022. The return on the trade was -31.70%.
What is Jesse Shefferman's role in Protara Therapeutics?
Jesse Shefferman's role in Protara Therapeutics is CEO & President, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.